Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Antiandrogen withdrawal (AAW) response is the paradoxical decrease in prostate-specific antigen (PSA) following the withdrawal of antiandrogen in patients with advanced prostate cancer. Currently, the reported literature on the proportion of patients exhibiting AAW response and the differences in PSA response between the types of antiandrogens is unclear.
Methods: This review aimed to explore the PSA response to AAW and to identify if the response depends on the type of antiandrogens. A literature search was performed using databases PubMed, Cochrane and EMBASE with a cut-off date of 23rd of November 2020. Studies reporting on outcomes of AAW and prostate cancer were included. Studies were screened by two reviewers and relevant data extracted. Meta-analysis of outcomes was reported using random-effects and fixed-effects model. A subgroup analysis was performed for type of antiandrogen.
Results: From 450 studies, 23 were included with a total of 1474 patients with advanced prostate cancer were available for further analysis. Overall, 395 (26%) patients had any reduction in PSA levels (95% CI: 20-32%) and 183 (11%) patients had a ≥50% reduction in PSA levels (95% CI: 6-16%). Among the 1212 patients on first-generation antiandrogens, 30% (95% CI: 23-38%) had any PSA decline with 15% patients having a ≥50% PSA decline (95% CI: 8-22%). In contrast, among the 108 patients on second-generation antiandrogens, 7% (95% CI: 0-13%) had any PSA decline and only 1% (95% CI: 0-5%) had a ≥50% PSA decline. Also, among the 154 patients on androgen synthesis inhibitors, 26% (95% CI: 19-33%) had any PSA decline and only 4% (95% CI: 0-13%) had a ≥50% PSA decline.
Conclusions: One-fourth of patients treated with AAW show a PSA response. However, PSA response to AAW is uncommon with second-generation antiandrogens and androgen synthesis inhibitors. Further research is required to understand the differences in response between the types of antiandrogen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41391-021-00337-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Triplet Therapy Showing Remarkable Efficacy for Multiorgan Metastatic Recurrence After Radical Prostatectomy in Prostate Cancer.
IJU Case Rep
September 2025
Department of Urology, Faculty of Medicine, Saga University, Saga, Japan.
Introduction: We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy.
Case Presentation: A 70-year-old man with relapsed metastatic castration-sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL.
Effect of bone marrow disease on hematologic toxicity and response to [Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging.
Eur J Nucl Med Mol Imaging
September 2025
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.
Purpose: Despite the effectiveness of [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), hematologic toxicity remains a concern, particularly in patients with bone metastases. This study evaluated whether the extent, intensity, and heterogeneity of bone disease on pretreatment PSMA-PET/CT were associated with hematologic toxicity, PSA response, and overall survival (OS) in mCRPC patients treated with [Lu]Lu-PSMA-617.
Methods: This retrospective study included 96 mCRPC patients who underwent pretreatment PSMA-PET/CT and received standard-of-care [Lu]Lu-PSMA-617.
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Invest New Drugs
September 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
As monotherapy, PARP inhibitors have little cytotoxic effect in tumors without homologous recombinant repair (HRR) alterations. Supported by preclinical models, we hypothesized that the PARP inhibitor talazoparib in combination with temozolomide chemotherapy could induce DNA damage leading to cell death and tumor response in patients with metastatic castration-resistant prostate cancer (mCRPC) without HRR alterations. In this phase 1b/2 trial (NCT04019327; registration date July 11, 2019), patients with progressive mCRPC without HRR mutations who failed at least one androgen receptor signaling inhibitor were enrolled in escalating doses of intermittent talazoparib plus temozolomide to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) in Phase 1b.
View Article and Find Full Text PDFTetrahedral DNA Framework-Engineered Magnetic Nanozyme for Visual Biomarker Sensing via Alkaline Phosphatase-Triggered Signal Switching.
Anal Chem
September 2025
School of Materials Science and Engineering, Shanghai University of Engineering Science, Shanghai 201620, China.
Point-of-care (POC) detection of prostate-specific antigen (PSA) is critical for the early screening and monitoring of prostate cancer (PCa), which facilitates timely intervention and personalized treatment. However, existing POC platforms suffer from inadequate detection sensitivities, susceptibility to matrix interference, and complex sample pretreatment. To address these issues, we proposed a naked-eye and colorimetric sensing platform based on magnetic nanozyme (FeO@ZIF-67@Pt) integrated with a tetrahedral DNA framework (TDF) and alkaline phosphatase (ALP)-triggered hydrolysis reaction for PSA detection with superior sensing performances.
View Article and Find Full Text PDFProstate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.
Prostate
September 2025
Instituto Valenciano de Oncología, Valencia, Spain.
Background: PSA response to apalutamide combined with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) has been linked to prognosis. Post hoc analyses from clinical trials suggest that PSA levels at 6 months are critical for predicting radiographic progression-free survival (rPFS) and overall survival (OS). Real-world evidence (RWE) is needed to confirm these findings.
View Article and Find Full Text PDF